Company Filing History:
2 out of 488 
1 out of 90 Years Active: 2002-2013
Title: The Innovations of Robert E Atchison
Introduction
Robert E Atchison is a notable inventor based in San Francisco, CA. He has made significant contributions to the field of biomedical research, particularly in the regulation of angiogenesis and tumorigenesis. With a total of 3 patents, Atchison's work has implications for cancer diagnosis and therapy.
Latest Patents
Atchison's latest patents include groundbreaking inventions related to the modulation of angiogenesis and tumorigenesis. One of his patents focuses on the regulation of angiogenesis, detailing methods for identifying and utilizing agents such as small organic molecules, antibodies, and nucleic acids that can modulate endothelial cell haptotaxis. This invention aims to enhance the understanding of angiogenesis and its role in cancer. Another patent specifically addresses nucleic acids encoding C1-angiogenesis protein, also known as integrin-linked kinase associated protein (ILKAP). This invention provides methods for identifying agents that modulate angiogenesis through ILKAP-related pathways, further contributing to cancer research.
Career Highlights
Throughout his career, Robert E Atchison has worked with prominent organizations, including Rigel Pharmaceuticals and the J. David Gladstone Institutes. His experience in these institutions has allowed him to collaborate with leading experts in the field and advance his research.
Collaborations
Atchison has collaborated with notable colleagues such as Mark A Goldsmith and Roberto F Speck. These partnerships have enriched his research and contributed to the development of innovative solutions in the biomedical field.
Conclusion
Robert E Atchison's contributions to the field of angiogenesis and tumorigenesis highlight his role as a significant inventor. His patents not only advance scientific understanding but also pave the way for potential therapeutic applications in cancer treatment.